The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?
Open accessAbstract
In this review we consider how cell specific recombinant monoclonal antibody (Mab) production by engineered mammalian cells can be improved. Whilst it is generally recognized that Mab production is limited post‐transcriptionally at folding and assembly reactions, genetic engineering strategies based on overexpression of individual chaperones or foldases in mammalian cells have not reliably increased cell specific Mab production. Given that recent studies have established that chaperones and foldases themselves exist in a large multiprotein complex, which may coordinate the sequential processing of Mabs, we propose that global expansion of all components of the secretory pathway will likely be necessary to generically improve recombinant Mab production by mammalian cells. In this context, what can be learnt from nature? Important recent studies have delineated some of the main cellular pathways involved in the differentiation of B‐cells into nature's own high level Mab producers, plasma cells. This is achieved by a dramatic re‐programming of cellular function where the coordinated expansion of metabolic and secretory machinery precedes Ig production, then is maintained by induction of a key intracellular signaling pathway, the unfolded protein response (UPR). Here we review genetic engineering strategies to increase cell specific production rate and discuss whether manipulation of intracellular signaling systems such as the UPR will provide a novel means to engineer mammalian cells for high level recombinant Mab production. © 2005 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sriburi, R., Jackowski, S., Mori, K., & Brewer, J. W. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200406136 · Cited by 653
Relationship between cell size, cell cycle and specific recombinant protein productivity
Lloyd, D. R., Holmes, P., Jackson, L. P., Emery, A. N., & Al-Rubeai, M. (2000) · Cytotechnology · doi:10.1023/a:1008103730027 · Cited by 93
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Birch, J. R., & Racher, A. J. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.12.006 · Cited by 471
Dreesen, I. A. J., & Fussenegger, M. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22990 · Cited by 110
Omasa, T., Takami, T., Ohya, T., Kiyama, E., Hayashi, T., Nishii, H., Miki, H., Kobayashi, K., Honda, K., & Ohtake, H. (2008) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.106.568 · Cited by 57
Detailed understanding of enhanced specific antibody productivity in NS0 myeloma cells
Khoo, S. H. G., & Al‐Rubeai, M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22041 · Cited by 38
Metadata
- Authors
- Dinnis, D. M., & James, D. C.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2005-05-05
- Volume
- 91
- Issue
- 2
- Pages
- 180-189
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2072835990
- Cited by
- 159
- References
- 2
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.